The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Neoadjuvant chemoradiation (CRT) with or without panitumumab (Pan) in patients with K-ras-unmutated, locally advanced rectal cancer (LARC): A randomized multicenter phase II trial (SAKK 41/07).
D. Helbling
No relevant relationships to disclose
G. Bodoky
Consultant or Advisory Role - Amgen; Roche
Honoraria - Amgen; Novartis; Pfizer; Roche
O. Gautschi
No relevant relationships to disclose
H. Sun
No relevant relationships to disclose
F. Bosman
No relevant relationships to disclose
B. Gloor
No relevant relationships to disclose
R. Burkhard
No relevant relationships to disclose
R. C. Winterhalder
No relevant relationships to disclose
A. Madlung
No relevant relationships to disclose
D. Rauch
No relevant relationships to disclose
P. Saletti
No relevant relationships to disclose
L. A. Widmer
No relevant relationships to disclose
M. M. Borner
No relevant relationships to disclose
D. Baertschi
No relevant relationships to disclose
P. Yan
No relevant relationships to disclose
D. Koeberle
No relevant relationships to disclose